Mikkel Thor Olsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mikkel Thor Olsen has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Carina Kirstine Klarskov
Department of Endocrinology and Nephrology, Copenhagen University Hospital, Copenhagen, Denmark
8 shared publications Peter Lommer Kristensen
Department of Endocrinology and Nephrology, Copenhagen University Hospital—North Zealand , Hilleroed 3400
8 shared publications- Peter Lommer Kristensen
Department of Endocrinology and Nephrology Nordsjællands Hospital Hillerød Denmark
7 shared publications Suzanne Lunding
Department of Infectious Diseases Herlev‐Gentofte Hospital Herlev Denmark
7 shared publications- Ulrik Pedersen-Bjergaard
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
7 shared publications Birgitte Lindegaard
Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
6 shared publications
Latest Publications
- 22 September 2026
- Published by American Diabetes Association in Diabetes Care
An International Position Statement on Practical Approaches for Inpatient Continuous Glucose Monitoring, Insulin Pumps, and Automated Insulin Delivery Systems in Adults
There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems in hospital settings. The goal with this position statement is to facilitate effective and safe use of these devices to improve glycemic management, enhance outcomes, and contribute to standardization efforts in initiating or continuing the use of these devices in hospitals for non–critically ill hospitalized adults. The topics covered include selection criteria for management with diabetes technologies, CGM-derived glycemic metrics and goals for adults with diabetes, insulin titration and administration guidelines, perioperative care, CGM alarm settings for hypoglycemia and hyperglycemia, clinical staff training and workflows, integration of device data with the electronic health record, imaging tests considerations, and discharge planning.
- 22 September 2026
- Published by American Diabetes Association in Diabetes Care
An International Position Statement on Practical Approaches for Inpatient Continuous Glucose Monitoring, Insulin Pumps, and Automated Insulin Delivery Systems in Adults
There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems in hospital settings. The goal with this position statement is to facilitate effective and safe use of these devices to improve glycemic management, enhance outcomes, and contribute to standardization efforts in initiating or continuing the use of these devices in hospitals for non–critically ill hospitalized adults. The topics covered include selection criteria for management with diabetes technologies, CGM-derived glycemic metrics and goals for adults with diabetes, insulin titration and administration guidelines, perioperative care, CGM alarm settings for hypoglycemia and hyperglycemia, clinical staff training and workflows, integration of device data with the electronic health record, imaging tests considerations, and discharge planning.
- Open Access
- 22 September 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (12) , 3409-3424
An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults
There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps and automated insulin delivery (AID) systems in hospital settings. The goal with this position statement is to facilitate effective and safe use of these devices to improve glycaemic management, enhance outcomes and contribute to standardisation efforts in initiating or continuing the use of these devices in hospitals for non-critically ill hospitalised adults. The topics covered include selection criteria for management with diabetes technologies, CGM-derived glycaemic metrics and goals for adults with diabetes, insulin titration and administration guidelines, perioperative care, CGM alarm settings for hypoglycaemia and hyperglycaemia, clinical staff training and workflows, integration of device data with the electronic health record, imaging tests considerations and discharge planning. Graphical Abstract
- 22 September 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (12) , 3409-3424
Open AccessAn international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults
There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps and automated insulin delivery (AID) systems in hospital settings. The goal with this position statement is to facilitate effective and safe use of these devices to improve glycaemic management, enhance outcomes and contribute to standardisation efforts in initiating or continuing the use of these devices in hospitals for non-critically ill hospitalised adults. The topics covered include selection criteria for management with diabetes technologies, CGM-derived glycaemic metrics and goals for adults with diabetes, insulin titration and administration guidelines, perioperative care, CGM alarm settings for hypoglycaemia and hyperglycaemia, clinical staff training and workflows, integration of device data with the electronic health record, imaging tests considerations and discharge planning. Graphical Abstract
- 24 June 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Automated Insulin Delivery Systems in Hospitals: A Systematic Review with Meta-Analysis
Inpatient diabetes management is challenging due to acute illness, variable insulin requirements, and reliance on intermittent point-of-care glucose testing. Both hyperglycemia and hypoglycemia are associated with increased costs, length of stay, morbidity, and mortality. However, efforts to achieve tighter glycemic targets are often limited by the risk of iatrogenic hypoglycemia. Notably, hypoglycemia (glucose N = 142 [with and without preexisting diabetes]) were identified. Meta-analysis of RCTs in the non-ICU setting showed that AID increased TIR by 24.6 percentage points (95% confidence interval 20.7–28.5). A meta-analysis on ICU data could not be conducted. Across all settings, AID was associated with reduced hyperglycemia without an increase in hypoglycemia. Clinical outcomes were sparsely reported. AID systems can be safely and effectively used in non-ICU hospital settings to improve glycemic outcomes. Larger, multicenter trials are needed to confirm clinical benefits and address implementation challenges.
- 24 June 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Automated Insulin Delivery Systems in Hospitals: A Systematic Review with Meta-Analysis
Inpatient diabetes management is challenging due to acute illness, variable insulin requirements, and reliance on intermittent point-of-care glucose testing. Both hyperglycemia and hypoglycemia are associated with increased costs, length of stay, morbidity, and mortality. However, efforts to achieve tighter glycemic targets are often limited by the risk of iatrogenic hypoglycemia. Notably, hypoglycemia (glucose N = 142 [with and without preexisting diabetes]) were identified. Meta-analysis of RCTs in the non-ICU setting showed that AID increased TIR by 24.6 percentage points (95% confidence interval 20.7–28.5). A meta-analysis on ICU data could not be conducted. Across all settings, AID was associated with reduced hyperglycemia without an increase in hypoglycemia. Clinical outcomes were sparsely reported. AID systems can be safely and effectively used in non-ICU hospital settings to improve glycemic outcomes. Larger, multicenter trials are needed to confirm clinical benefits and address implementation challenges.
- 10 April 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (6) , e70321
Acute kidney injury in hospitalised patients with type 2 diabetes: Associations with continuous glucose monitoring‐based glucose levels, mortality, and ICU admission
Aims: Acute kidney injury (AKI) may increase the risk of hypoglycaemia in patients with diabetes due to reduced insulin clearance and altered glucose metabolism. However, the impact of AKI on glycaemic status in non‐critically ill hospitalised patients with diabetes is not well understood. Methods: We included 166 hospitalised patients with type 2 diabetes on basal‐bolus insulin monitored by continuous glucose monitoring (CGM). Kidney function was measured daily via plasma creatinine levels, and AKI was staged per Kidney Disease Improving Global Outcomes (KDIGO) guidelines. Multivariate models assessed associations between kidney function and CGM‐based glycaemic outcomes. Results: AKI correlated with a 7.3%‐point (95% CI 0.3–14.2) reduction in time in range (TIR, 3.9–10.0 mmol/L), driven by increased time above range (TAR, >10.0 mmol/L), with no significant change in time below range (TBR, <3.9 mmol/L). AKI was also associated with approximately a tenfold increase in the risk of in‐hospital mortality and intensive care unit (ICU) admission, and the risk of being readmitted within 30 days was twice as high. TIR decreased by 7.6%‐point (95% CI 2.6–12.5) for each 100 μmol/L increase in plasma creatinine levels. Conclusion: AKI and high plasma creatinine are associated with hyperglycemia, in‐hospital mortality, referral to ICU, and 30‐day unscheduled readmissions in hospitalised patients with type 2 diabetes. These findings challenge the prevailing focus on hypoglycemia prevention during AKI, emphasising the importance of addressing hyperglycemia as well.
- 10 April 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (6) , e70321
Acute kidney injury in hospitalised patients with type 2 diabetes: Associations with continuous glucose monitoring‐based glucose levels, mortality, and ICU admission
Aims: Acute kidney injury (AKI) may increase the risk of hypoglycaemia in patients with diabetes due to reduced insulin clearance and altered glucose metabolism. However, the impact of AKI on glycaemic status in non‐critically ill hospitalised patients with diabetes is not well understood. Methods: We included 166 hospitalised patients with type 2 diabetes on basal‐bolus insulin monitored by continuous glucose monitoring (CGM). Kidney function was measured daily via plasma creatinine levels, and AKI was staged per Kidney Disease Improving Global Outcomes (KDIGO) guidelines. Multivariate models assessed associations between kidney function and CGM‐based glycaemic outcomes. Results: AKI correlated with a 7.3%‐point (95% CI 0.3–14.2) reduction in time in range (TIR, 3.9–10.0 mmol/L), driven by increased time above range (TAR, >10.0 mmol/L), with no significant change in time below range (TBR, <3.9 mmol/L). AKI was also associated with approximately a tenfold increase in the risk of in‐hospital mortality and intensive care unit (ICU) admission, and the risk of being readmitted within 30 days was twice as high. TIR decreased by 7.6%‐point (95% CI 2.6–12.5) for each 100 μmol/L increase in plasma creatinine levels. Conclusion: AKI and high plasma creatinine are associated with hyperglycemia, in‐hospital mortality, referral to ICU, and 30‐day unscheduled readmissions in hospitalised patients with type 2 diabetes. These findings challenge the prevailing focus on hypoglycemia prevention during AKI, emphasising the importance of addressing hyperglycemia as well.
- 3 April 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Glycaemia Around Exercise in People With Type 1 Diabetes With and Without a Bolus Calculator: A Post Hoc Analysis of a Randomised Controlled Trial
Introduction: Exercise-induced hypoglycaemia is a barrier to physical activity in people with type 1 diabetes. Clinical guidelines recommend reducing prandial insulin before aerobic exercise, but adherence is limited. Insulin bolus calculators may support implementation of these recommendations, yet their effect on glucose around exercise is not well described. Methods: This post-hoc analysis used data from a randomised crossover trial including 17 adults with type 1 diabetes treated with multiple daily injections. Participants completed 45 minutes of moderate-intensity cycling after breakfast using either the Hedia Diabetes Assistant (HDA) bolus calculator smartphone app (50% bolus reduction) or their habitual diabetes management. Continuous glucose monitoring data were analysed from an hour before to an hour after exercise. Linear mixed-effects models were used to estimate the glucose rate of change. Results: In all participants, glucose increased before exercise (0.040 mmol/L/min [95% confidence interval [CI] = 0.030, 0.050]), declined during exercise (−0.039 mmol/L/min [95% CI = −0.058, −0.020]), and plateaued post-exercise (0.002 mmol/L/min [95% CI = −0.025, 0.030]). Pre-exercise, the increase in glucose was higher when using HDA (mean difference = 0.043 mmol/L/min [0.023, 0.062]), lower during exercise (mean difference = 0.030 mmol/L/min [95% CI = −0.003, 0.063]), and similar post-exercise (mean difference = 0.002 mmol/L/min [95% CI = −0.025, 0.030]). Two hypoglycaemic events occurred during control sessions and none during HDA sessions. Discussion: The use of an insulin bolus calculator implementing insulin reduction appeared to reduce the glucose decline during aerobic exercise, potentially reducing hypoglycaemia risk. However, increases in pre-exercise glucose indicate that a 50% reduction for moderate-intensity exercise may be excessive for some.
- 3 April 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Glycaemia Around Exercise in People With Type 1 Diabetes With and Without a Bolus Calculator: A Post Hoc Analysis of a Randomised Controlled Trial
Introduction: Exercise-induced hypoglycaemia is a barrier to physical activity in people with type 1 diabetes. Clinical guidelines recommend reducing prandial insulin before aerobic exercise, but adherence is limited. Insulin bolus calculators may support implementation of these recommendations, yet their effect on glucose around exercise is not well described. Methods: This post-hoc analysis used data from a randomised crossover trial including 17 adults with type 1 diabetes treated with multiple daily injections. Participants completed 45 minutes of moderate-intensity cycling after breakfast using either the Hedia Diabetes Assistant (HDA) bolus calculator smartphone app (50% bolus reduction) or their habitual diabetes management. Continuous glucose monitoring data were analysed from an hour before to an hour after exercise. Linear mixed-effects models were used to estimate the glucose rate of change. Results: In all participants, glucose increased before exercise (0.040 mmol/L/min [95% confidence interval [CI] = 0.030, 0.050]), declined during exercise (−0.039 mmol/L/min [95% CI = −0.058, −0.020]), and plateaued post-exercise (0.002 mmol/L/min [95% CI = −0.025, 0.030]). Pre-exercise, the increase in glucose was higher when using HDA (mean difference = 0.043 mmol/L/min [0.023, 0.062]), lower during exercise (mean difference = 0.030 mmol/L/min [95% CI = −0.003, 0.063]), and similar post-exercise (mean difference = 0.002 mmol/L/min [95% CI = −0.025, 0.030]). Two hypoglycaemic events occurred during control sessions and none during HDA sessions. Discussion: The use of an insulin bolus calculator implementing insulin reduction appeared to reduce the glucose decline during aerobic exercise, potentially reducing hypoglycaemia risk. However, increases in pre-exercise glucose indicate that a 50% reduction for moderate-intensity exercise may be excessive for some.
- 1 October 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (10) , 839-848
Imputation Model for Glucose Values Above the Upper Detection Limit for Continuous Glucose Monitors
Objective: All continuous glucose monitors (CGMs) have an upper detection limit, typically of 22.2 mmol/L. This might bias CGM metrics. We aimed to develop and validate a statistical model for imputing values above this limit. Methods: We analyzed CGM data from 85 inpatients with type 2 diabetes, 705 outpatients with type 1 diabetes, and 27 outpatients with type 2 diabetes. A Bayesian nonparametric latent Gaussian process regression model was applied to the CGM data intentionally right censored for the top 5%, 10%, 20%, and 30% and compared with the uncensored CGM data by the bias, mean squared error (MSE), and coefficient of determination ( R 2 ) of mean glucose, standard deviation (SD), and coefficient of variation (CV). Results: In hospitalized patients with diabetes, outpatients with type 1 diabetes, and outpatients with type 2 diabetes for 5% to 30% right censoring, respectively, the bias on mean glucose after imputation ranged from −0.012 to 0.362, −0.018 to 0.485, and −0.008 to 0.130, respectively. Bias on SD ranged from −0.024 to 0.226, −0.033 to 0.381, and −0.016 to 0.138, respectively. Bias on CV ranged from −0.207 to 1.543, −0.316 to 2.609, and −0.222 to 1.721, respectively. Similar results indicating good performance of the imputation model were observed for MSE and R 2 . Conclusions: An imputation model for glucose values above the upper detection limit of CGMs was developed and validated in various populations. This enables a more unbiased quantification of CGM metrics for patients with severe hyperglycemia.
- 1 October 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (10) , 839-848
Imputation Model for Glucose Values Above the Upper Detection Limit for Continuous Glucose Monitors
Objective: All continuous glucose monitors (CGMs) have an upper detection limit, typically of 22.2 mmol/L. This might bias CGM metrics. We aimed to develop and validate a statistical model for imputing values above this limit. Methods: We analyzed CGM data from 85 inpatients with type 2 diabetes, 705 outpatients with type 1 diabetes, and 27 outpatients with type 2 diabetes. A Bayesian nonparametric latent Gaussian process regression model was applied to the CGM data intentionally right censored for the top 5%, 10%, 20%, and 30% and compared with the uncensored CGM data by the bias, mean squared error (MSE), and coefficient of determination ( R 2 ) of mean glucose, standard deviation (SD), and coefficient of variation (CV). Results: In hospitalized patients with diabetes, outpatients with type 1 diabetes, and outpatients with type 2 diabetes for 5% to 30% right censoring, respectively, the bias on mean glucose after imputation ranged from −0.012 to 0.362, −0.018 to 0.485, and −0.008 to 0.130, respectively. Bias on SD ranged from −0.024 to 0.226, −0.033 to 0.381, and −0.016 to 0.138, respectively. Bias on CV ranged from −0.207 to 1.543, −0.316 to 2.609, and −0.222 to 1.721, respectively. Similar results indicating good performance of the imputation model were observed for MSE and R 2 . Conclusions: An imputation model for glucose values above the upper detection limit of CGMs was developed and validated in various populations. This enables a more unbiased quantification of CGM metrics for patients with severe hyperglycemia.
- Open Access
- 28 August 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (10) , bvaf137
Glycemic Levels and Insulin Use Daily and During Hospital Shifts in Hospitalized Patients With Type 2 Diabetes
Objective: To characterize glucose levels and insulin use daily and during hospital shifts throughout hospitalization, which might inform treatment planning and improve outcomes. Methods: This is a post hoc analysis from a 2-center randomized trial with 166 nonintensive care unit hospitalized patients with type 2 diabetes. Diabetes management was performed by regular staff, guided by diabetes teams using insulin titration algorithms based on either point-of-care glucose testing (POC arm) or continuous glucose monitoring (CGM arm). POC-arm participants wore blinded continuous glucose monitors. The primary outcome was the development in time in range (TIR) (3.9-10.0 mmol/L) between arms during hospitalization. Results: TIR improved progressively to nearly 90% in the CGM arm by discharge, compared to 60% in the POC arm, which plateaued after day 5 (P < .001). Both arms showed the lowest TIR and highest insulin use during the day shift (07:00-15:00 hours). Correctional insulin doses were lower in the CGM arm compared to the POC arm across all shifts: 0.7 IU (±0.3) lower during day shifts (07:00-15:00 hours, P = .016), 1.2 IU (±0.4) lower during evening shifts (15:01-23:00 hours, P = .005), and 0.3 IU (±0.1) lower during night shifts (23:01-06:59 hours, P = .038). Prandial insulin doses were 1.1 IU (±0.5) lower during evening shifts in the CGM arm (P = .021). Conclusion: TIR improved continuously to nearly 90% in the CGM arm by discharge, compared to 60% in the POC arm, which plateaued after day 5, despite lower daily insulin doses in the CGM arm. These findings underscore the sustained effectiveness of CGM in enhancing glycemic levels throughout the entire duration of hospitalization.
- 28 August 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (10) , bvaf137
Open AccessGlycemic Levels and Insulin Use Daily and During Hospital Shifts in Hospitalized Patients With Type 2 Diabetes
Objective: To characterize glucose levels and insulin use daily and during hospital shifts throughout hospitalization, which might inform treatment planning and improve outcomes. Methods: This is a post hoc analysis from a 2-center randomized trial with 166 nonintensive care unit hospitalized patients with type 2 diabetes. Diabetes management was performed by regular staff, guided by diabetes teams using insulin titration algorithms based on either point-of-care glucose testing (POC arm) or continuous glucose monitoring (CGM arm). POC-arm participants wore blinded continuous glucose monitors. The primary outcome was the development in time in range (TIR) (3.9-10.0 mmol/L) between arms during hospitalization. Results: TIR improved progressively to nearly 90% in the CGM arm by discharge, compared to 60% in the POC arm, which plateaued after day 5 (P < .001). Both arms showed the lowest TIR and highest insulin use during the day shift (07:00-15:00 hours). Correctional insulin doses were lower in the CGM arm compared to the POC arm across all shifts: 0.7 IU (±0.3) lower during day shifts (07:00-15:00 hours, P = .016), 1.2 IU (±0.4) lower during evening shifts (15:01-23:00 hours, P = .005), and 0.3 IU (±0.1) lower during night shifts (23:01-06:59 hours, P = .038). Prandial insulin doses were 1.1 IU (±0.5) lower during evening shifts in the CGM arm (P = .021). Conclusion: TIR improved continuously to nearly 90% in the CGM arm by discharge, compared to 60% in the POC arm, which plateaued after day 5, despite lower daily insulin doses in the CGM arm. These findings underscore the sustained effectiveness of CGM in enhancing glycemic levels throughout the entire duration of hospitalization.
- 28 July 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (10) , e70114
Satisfaction with continuous glucose monitoring and diabetes care among hospitalised patients with type 2 diabetes managed by inpatient diabetes teams
Aims: Continuous glucose monitoring (CGM) is increasingly recognised as a valuable tool in the hospital setting, with evidence supporting its accuracy and potential for improving glycaemic and clinical outcomes. However, patient perspectives on the use of CGM in the hospital setting remain underexplored. This study investigates patient satisfaction with CGM during hospitalisation.Methods: This analysis included 166 hospitalised non‐intensive care unit (non‐ICU) patients with type 2 diabetes from the DIAbetes TEam and Cgm (DIATEC) trial. Participants were randomised to either point‐of‐care (POC) glucose testing (n = 82) or CGM (n = 84) for glucose monitoring during their hospital stay and were managed by inpatient diabetes teams. At discharge, patients completed a survey developed for this specific study, assessing their satisfaction with the diabetes management, with a focus on glucose monitoring methods.Results: Overall satisfaction with the diabetes treatment during hospitalisation was similar in both groups, with 77% of patients in each group reporting being satisfied or very satisfied (p = 0.188). Regarding glucose assessment, 75% in the CGM group preferred CGM over POC glucose testing (p < 0.001). In the CGM group, 95% felt comfortable with CGM being the primary method for glucose management (p < 0.001). Approximately 5% reported discomfort from wearing the CGM, mainly due to itching from the sensor. Most patients (95%) in both groups were comfortable with their diabetes management being handled by inpatient diabetes teams (p < 0.001).Conclusions: Satisfaction with CGM among non‐ICU patients with type 2 diabetes managed by inpatient diabetes teams was high, highlighting CGM's potential to enhance patient care in the hospital setting.
- 28 July 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (10) , e70114
Satisfaction with continuous glucose monitoring and diabetes care among hospitalised patients with type 2 diabetes managed by inpatient diabetes teams
Aims: Continuous glucose monitoring (CGM) is increasingly recognised as a valuable tool in the hospital setting, with evidence supporting its accuracy and potential for improving glycaemic and clinical outcomes. However, patient perspectives on the use of CGM in the hospital setting remain underexplored. This study investigates patient satisfaction with CGM during hospitalisation.Methods: This analysis included 166 hospitalised non‐intensive care unit (non‐ICU) patients with type 2 diabetes from the DIAbetes TEam and Cgm (DIATEC) trial. Participants were randomised to either point‐of‐care (POC) glucose testing (n = 82) or CGM (n = 84) for glucose monitoring during their hospital stay and were managed by inpatient diabetes teams. At discharge, patients completed a survey developed for this specific study, assessing their satisfaction with the diabetes management, with a focus on glucose monitoring methods.Results: Overall satisfaction with the diabetes treatment during hospitalisation was similar in both groups, with 77% of patients in each group reporting being satisfied or very satisfied (p = 0.188). Regarding glucose assessment, 75% in the CGM group preferred CGM over POC glucose testing (p < 0.001). In the CGM group, 95% felt comfortable with CGM being the primary method for glucose management (p < 0.001). Approximately 5% reported discomfort from wearing the CGM, mainly due to itching from the sensor. Most patients (95%) in both groups were comfortable with their diabetes management being handled by inpatient diabetes teams (p < 0.001).Conclusions: Satisfaction with CGM among non‐ICU patients with type 2 diabetes managed by inpatient diabetes teams was high, highlighting CGM's potential to enhance patient care in the hospital setting.
- 23 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5844-5851
The association between inflammation and glucose levels in hospitalised patients with type 2 diabetes
Aims: Stress‐induced hyperglycaemia can exacerbate existing diabetes. However, the relationship between inpatient inflammation and glucose levels is not well understood. Materials and Methods: This post hoc analysis utilised data from the DIATEC trial ( N = 166), a two‐arm randomised controlled trial comparing glucose management with real‐time continuous glucose monitoring (CGM) or point‐of‐care glucose testing in non‐intensive care unit (non‐ICU) patients with type 2 diabetes treated with a basal‐bolus insulin regimen. Inflammation was measured as C‐reactive protein (CRP) levels daily, and its association with daily glycaemic outcomes and insulin doses was assessed. Results: For every 100 mg/dL increase in CRP, time in range 3.9–10.0 mmol/L (70–180 mg/dL) decreased by 3.6%‐points (95% CI: 1.2–6.1, p = 0.004). An interaction was found between high CRP (>75.0 mg/dL) and high HbA1c (>51.0 mmol/mol or 6.8%), associated with an 8.9%‐point reduction in TIR (95% CI: 3.8–14.1). Time above range >10.0 mmol/L (>180 mg/dL) increased by 3.3%‐points (95% CI: 0.8–5.8, p = 0.009), and mean glucose increased by 0.2 mmol/L (95% CI: 0.02–0.4) (4.0 mg/dL, 95% CI: 0.4–7.0) for every 100 mg/dL increase in CRP. No significant associations were found between CRP and time below range <3.9 mmol/L ( 0.05). Conclusions: Elevated CRP levels only modestly increased glucose levels. This suggests that inflammation during hospitalisation has a limited effect on glucose levels in non‐ICU patients with type 2 diabetes.
- 23 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5844-5851
The association between inflammation and glucose levels in hospitalised patients with type 2 diabetes
Aims: Stress‐induced hyperglycaemia can exacerbate existing diabetes. However, the relationship between inpatient inflammation and glucose levels is not well understood. Materials and Methods: This post hoc analysis utilised data from the DIATEC trial ( N = 166), a two‐arm randomised controlled trial comparing glucose management with real‐time continuous glucose monitoring (CGM) or point‐of‐care glucose testing in non‐intensive care unit (non‐ICU) patients with type 2 diabetes treated with a basal‐bolus insulin regimen. Inflammation was measured as C‐reactive protein (CRP) levels daily, and its association with daily glycaemic outcomes and insulin doses was assessed. Results: For every 100 mg/dL increase in CRP, time in range 3.9–10.0 mmol/L (70–180 mg/dL) decreased by 3.6%‐points (95% CI: 1.2–6.1, p = 0.004). An interaction was found between high CRP (>75.0 mg/dL) and high HbA1c (>51.0 mmol/mol or 6.8%), associated with an 8.9%‐point reduction in TIR (95% CI: 3.8–14.1). Time above range >10.0 mmol/L (>180 mg/dL) increased by 3.3%‐points (95% CI: 0.8–5.8, p = 0.009), and mean glucose increased by 0.2 mmol/L (95% CI: 0.02–0.4) (4.0 mg/dL, 95% CI: 0.4–7.0) for every 100 mg/dL increase in CRP. No significant associations were found between CRP and time below range <3.9 mmol/L ( 0.05). Conclusions: Elevated CRP levels only modestly increased glucose levels. This suggests that inflammation during hospitalisation has a limited effect on glucose levels in non‐ICU patients with type 2 diabetes.
- 11 April 2025
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (5) , 1630-1635
Time at High Risk of Hypoglycemia: Validation of a Consensus-Based Continuous Glucose Monitoring-Metric for Hospitalized Patients
Background: Time at high risk of hypoglycemia (THRH), 3.9 to 5.6 mmol/L, is a continuous glucose monitoring (CGM)-based metric recommended for reporting in hospitalized patients. This study aims to validate THRH as a predictor of hypoglycemia. Methods: The CGM data from 166 non-intensive care unit (non-ICU) inpatients with type 2 diabetes from the DIATEC trial were analyzed. All participants received basal-bolus insulin therapy. Of these, 82 were monitored with point-of-care glucose testing and blinded CGM, while 84 had open CGM. Linear and negative binomial regression analyses assessed the relationship between THRH and time below range (TBR) (P < .001. A THRH threshold below 50% was linked to a TBR <3.9 mmol/L of less than 4%, as recommended. Similar results were observed during both day and night analyses and for point-of-care monitored patients, also for hypoglycemic events. Conclusions: The THRH is strongly associated with hypoglycemia in non-ICU hospitalized patients with type 2 diabetes on basal-bolus insulin. Aiming for THRH below 50% aligns with the recommended TBR target of <3.9 mmol/L below 4%, supporting THRH’s role in guiding hypoglycemia prevention strategies.
- 11 April 2025
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (5) , 1630-1635
Time at High Risk of Hypoglycemia: Validation of a Consensus-Based Continuous Glucose Monitoring-Metric for Hospitalized Patients
Background: Time at high risk of hypoglycemia (THRH), 3.9 to 5.6 mmol/L, is a continuous glucose monitoring (CGM)-based metric recommended for reporting in hospitalized patients. This study aims to validate THRH as a predictor of hypoglycemia. Methods: The CGM data from 166 non-intensive care unit (non-ICU) inpatients with type 2 diabetes from the DIATEC trial were analyzed. All participants received basal-bolus insulin therapy. Of these, 82 were monitored with point-of-care glucose testing and blinded CGM, while 84 had open CGM. Linear and negative binomial regression analyses assessed the relationship between THRH and time below range (TBR) (P < .001. A THRH threshold below 50% was linked to a TBR <3.9 mmol/L of less than 4%, as recommended. Similar results were observed during both day and night analyses and for point-of-care monitored patients, also for hypoglycemic events. Conclusions: The THRH is strongly associated with hypoglycemia in non-ICU hospitalized patients with type 2 diabetes on basal-bolus insulin. Aiming for THRH below 50% aligns with the recommended TBR target of <3.9 mmol/L below 4%, supporting THRH’s role in guiding hypoglycemia prevention strategies.